TAMPA, Fla. (Nov. 7, 2011) – Dr. Shivakumar Vignesh is searching for people who have pancreatic cystic tumors to participate in a research study at Moffitt Cancer Center.
The study will compare the specimens obtained from each person’s pancreatic cystic tumor using two different methods: endoscopic ultrasound-guided fine-needle aspiration of the cyst fluid and endoscopic ultrasound-guided brushing of the cyst wall. In addition, all participants will be considered as candidates for surgical removal of their cystic pancreatic tumors.
The goals are to identify the endoscopic ultrasound-guided sampling method with the highest tissue yield for the diagnosis of abnormal cellular development, and proteomic analysis of cyst fluid (to measure proteins that may serve as markers of early cancer) from the cystic pancreatic tumors.
“The objective of the study is to predict cancer risk,” added Vignesh, the head researcher in the study and an endoscopic oncologist at Moffitt.
Pancreatic cancer is the fourth-leading cause of cancer death in the United States. Only an estimated 25 percent of diagnosed patients will survive the first year of treatment. The disease is highly fatal because of the lack of reliable screening tests.
Vignesh is looking for 48 participants who meet the following criteria:
- You must be between 18 and 85 years old with a pancreatic cyst seen on a CT scan or MRI.
- You must meet the clinical criteria to undergo an endoscopic ultrasound with fine needle aspiration. This may be determined at a clinic visit with Vignesh.
However, participants must not have the following:
- Pancreatic cancer
- Recent pancreatitis, specifically an episode of pancreatitis within 4 weeks of study enrollment
- Coagulopathy (a disorder that affects the ability of the blood to coagulate)
- Thrombocytopenia (an abnormal drop in the number of platelets)
Interested participants will have a clinical consultation to determine eligibility.
Participants will be asked to consent to an endoscopic ultrasound-guided fine needle aspiration and an endoscopic ultrasound-guided brushing with the Echo Brush, an endoscopic device that is Food and Drug Administration-approved for sampling pancreatic cystic lesions and is used as standard of care for cystic pancreatic tumors. All participants will be considered as candidates for surgical removal of their cystic pancreatic tumors.
For more information on enrollment, contact Helen Jump at (813) 745-4834 or Helen.Jump@moffitt.org or Dr. Vignesh at (813) 745-8361 or Shivakumar.Vignesh@moffitt.org.
For detailed trial information, visit http://clinicaltrials.gov/ct2/show/NCT01455311. About Moffitt Cancer Center
Follow Moffitt on Facebook: www.facebook.com/MoffittCancerCenter
Follow Moffitt on Twitter: @MoffittNews
Follow Moffitt on YouTube: MoffittNews Located in Tampa, Moffitt Cancer Center is Florida’s only NCI Comprehensive Cancer Center, a designation that recognizes Moffitt’s excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 14 affiliates in Florida, one in Georgia, one in Pennsylvania and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. Moffitt marks a very important anniversary in 2011 – 25 years committed to one mission: to contribute to the prevention and cure of cancer. ###